Novartis AG (NVS)
Novartis AG (NVS) Stock Price, Analysis & Data
| Bid | 155.06 |
| Market Cap | 293.76B |
| Revenue (ttm) | 56.69B |
| Net Income (ttm) | 12.76B |
| Beta | 0.49 |
| EPS (ttm) | 6.61 |
| PE Ratio (ttm) | 23.38 |
| Forward PE | 15.76 |
| P/B (ttm) | 7.07 |
| P/S (ttm) | 5.18 |
| Earnings Date | Oct 27, 2026 |
| Ask | 155.12 |
| Volume | 1,321,939 |
| Avg. Volume (20D) | 1,864,506 |
| Open | 153.58 |
| Previous Close | 151.97 |
| Day's Range | 153.40 - 155.10 |
| 52-Week Range | 121.57 - 170.46 |
| Analyst | Hold |
| Price Target | 160.15 (3.62%) |
| Dividends | $4.74 (3.07%) |
| Ex-Dividend Date | Mar 11, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral...
Financial Performance
In 2025, Novartis's revenue was 56.67B, an increase of 9.57% compared to the previous year's 51.72B. Earnings were 13.98B, an increase of 17.11%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for NVS stock is "Hold". The 12-month stock price forecast is 160.15, which is upside of 3.62% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
